-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang Fourth Pharmaceutical Group has been listed on the "Top 100 Chinese Chemical Pharmaceutical Companies" list.
Category:
Time：2023-06-28
On the evening of June 27, the 2022 Mishi Conference (China Pharmaceutical and Health Industry Symbiosis Conference), hosted by Minenet, opened in Huzhou, Zhejiang Province. During the conference, the highly anticipated 2022 Top 100 Chinese Pharmaceutical Industry Rankings were released. Shijiazhuang Fourth Pharmaceutical Group was named among the “Top 100 Chinese Chemical Pharmaceutical Enterprises of 2022” thanks to its strong R&D capabilities and market influence, ranking 39th on the list.
On the evening of June 27, the 2022 Mishi Conference (China Pharmaceutical and Health Industry Symbiosis Conference), hosted by Minenet, opened in Huzhou, Zhejiang Province. During the conference, the highly anticipated 2022 Top 100 Chinese Pharmaceutical Industry Rankings were released. Shijiazhuang Fourth Pharmaceutical Group was named among the “Top 100 Chinese Chemical Pharmaceutical Enterprises of 2022” thanks to its strong R&D capabilities and market influence, ranking 39th on the list.
It is reported that the Mice Conference, one of China’s most authoritative, professional, and high-profile events in the pharmaceutical and healthcare industry, is themed “Quality Wins—New Cycle.” The conference aims to build a thought-sharing platform for industry-wide intellectual exchange and resource sharing by focusing on brand connectivity, insightful information, strategic foresight, and professional empowerment. This year’s ranking assessment centers on the innovation-driven force and professional promotion capabilities of pharmaceutical manufacturing enterprises. Specifically, the innovation-driven force is primarily evaluated based on comprehensive R&D investment indicators, while the professional promotion capability is rigorously defined according to quantitative data from end-user markets—namely, the final selection preferences of clinicians and patients. The final results are derived from a quantitative analysis that integrates exclusive data from Minenet across three major end-user segments and six key market segments.
In recent years, Shijiazhuang No.4 Pharmaceutical Group has actively been building a high-energy ecosystem for R&D and innovation, aligning its innovation chain with the industrial chain to continuously enhance the level and sophistication of its innovative development. Leveraging the group’s resource advantages, it has accelerated the research and development of specialty generic drugs, active pharmaceutical ingredients, innovative drugs, pharmaceutical packaging materials, and products undergoing consistency evaluations. As a result, the group has achieved synchronized development across the entire drug R&D and market transformation value chain, establishing a uniquely distinctive product portfolio and new competitive advantages in the industry. Currently, the group has nearly 200 projects under development; among them, several first-class new drugs—including ADN-9 for the treatment of liver fibrosis—have either been approved for clinical trials or have submitted applications for clinical trials. Over 100 new products are awaiting approval, and since the beginning of this year, the group has already secured 32 new product approvals. The group ranks among the top in China’s pharmaceutical companies in terms of both efficiency and volume of specialty generic drug R&D. Furthermore, the group has been listed twice on prestigious rankings: as one of the Top 30 Chinese Pharmaceutical Companies in R&D Comprehensive Strength in 2023 and as one of the Top 10 Chinese Chemical Pharmaceutical R&D Companies in 2023. With the industry’s overall scale continuing to expand, an increasingly abundant stream of innovative achievements, a gradually optimized product structure, and steadily improving economic quality, the group is well-positioned to achieve high-quality, efficient, and rapid development. In 2022, the group’s key economic indicators showed robust growth, and its business operations were vibrant and full of vitality.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license